CR20220476A - Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales - Google Patents
Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondrialesInfo
- Publication number
- CR20220476A CR20220476A CR20220476A CR20220476A CR20220476A CR 20220476 A CR20220476 A CR 20220476A CR 20220476 A CR20220476 A CR 20220476A CR 20220476 A CR20220476 A CR 20220476A CR 20220476 A CR20220476 A CR 20220476A
- Authority
- CR
- Costa Rica
- Prior art keywords
- neurodegenerative
- compositions
- treatment
- mitochondrial diseases
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980143P | 2020-02-21 | 2020-02-21 | |
| PCT/US2021/019113 WO2021168446A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220476A true CR20220476A (es) | 2023-05-31 |
Family
ID=77391353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220476A CR20220476A (es) | 2020-02-21 | 2021-02-22 | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240018146A1 (https=) |
| EP (1) | EP4106874A4 (https=) |
| JP (2) | JP2023515101A (https=) |
| KR (1) | KR20220158290A (https=) |
| CN (1) | CN115515682B (https=) |
| AU (1) | AU2021222053A1 (https=) |
| BR (1) | BR112022016614A2 (https=) |
| CA (1) | CA3168531A1 (https=) |
| CO (1) | CO2022013603A2 (https=) |
| CR (1) | CR20220476A (https=) |
| EC (1) | ECSP22074210A (https=) |
| IL (1) | IL295681B1 (https=) |
| MX (1) | MX2022010309A (https=) |
| PH (1) | PH12022552518A1 (https=) |
| WO (1) | WO2021168446A1 (https=) |
| ZA (1) | ZA202210409B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012129A (es) * | 2019-04-03 | 2022-01-31 | Mitokinin Inc | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. |
| CN119752781B (zh) * | 2025-03-04 | 2025-07-01 | 中国农业大学 | 缓解成熟卵子老化的组合物、培养液、产品及方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| TW200508224A (en) * | 2003-02-12 | 2005-03-01 | Bristol Myers Squibb Co | Cyclic derivatives as modulators of chemokine receptor activity |
| EA024006B1 (ru) * | 2006-02-02 | 2016-08-31 | Миллениум Фармасьютикалз, Инк. | Ингибиторы е1 активирующих ферментов |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| BRPI0918502A2 (pt) * | 2008-09-02 | 2015-12-01 | Sanofi Aventis | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos |
| WO2014124458A1 (en) * | 2013-02-11 | 2014-08-14 | The Regents Of The University Of California | Compositions and methods for treating neurodegenerative diseases |
| EP3641545A4 (en) * | 2017-06-21 | 2021-02-24 | Mitokinin, Inc. | COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE |
-
2021
- 2021-02-22 MX MX2022010309A patent/MX2022010309A/es unknown
- 2021-02-22 CR CR20220476A patent/CR20220476A/es unknown
- 2021-02-22 US US17/801,450 patent/US20240018146A1/en active Pending
- 2021-02-22 KR KR1020227032526A patent/KR20220158290A/ko active Pending
- 2021-02-22 AU AU2021222053A patent/AU2021222053A1/en active Pending
- 2021-02-22 WO PCT/US2021/019113 patent/WO2021168446A1/en not_active Ceased
- 2021-02-22 CN CN202180025593.5A patent/CN115515682B/zh active Active
- 2021-02-22 IL IL295681A patent/IL295681B1/en unknown
- 2021-02-22 EP EP21757063.9A patent/EP4106874A4/en active Pending
- 2021-02-22 JP JP2022550119A patent/JP2023515101A/ja not_active Withdrawn
- 2021-02-22 CA CA3168531A patent/CA3168531A1/en active Pending
- 2021-02-22 PH PH1/2022/552518A patent/PH12022552518A1/en unknown
- 2021-02-22 BR BR112022016614A patent/BR112022016614A2/pt unknown
-
2022
- 2022-09-20 ZA ZA2022/10409A patent/ZA202210409B/en unknown
- 2022-09-21 CO CONC2022/0013603A patent/CO2022013603A2/es unknown
- 2022-09-21 EC ECSENADI202274210A patent/ECSP22074210A/es unknown
-
2025
- 2025-05-09 JP JP2025078577A patent/JP7808226B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021168446A1 (en) | 2021-08-26 |
| MX2022010309A (es) | 2022-11-14 |
| CO2022013603A2 (es) | 2023-03-17 |
| IL295681A (en) | 2022-10-01 |
| JP2023515101A (ja) | 2023-04-12 |
| ZA202210409B (en) | 2024-01-31 |
| IL295681B1 (en) | 2026-04-01 |
| CN115515682A (zh) | 2022-12-23 |
| PH12022552518A1 (en) | 2024-03-11 |
| JP7808226B2 (ja) | 2026-01-28 |
| CN115515682B (zh) | 2024-06-21 |
| US20240018146A1 (en) | 2024-01-18 |
| CA3168531A1 (en) | 2021-08-26 |
| EP4106874A4 (en) | 2024-03-20 |
| BR112022016614A2 (pt) | 2022-12-13 |
| KR20220158290A (ko) | 2022-11-30 |
| EP4106874A1 (en) | 2022-12-28 |
| ECSP22074210A (es) | 2023-02-28 |
| AU2021222053A1 (en) | 2022-09-15 |
| JP2025142197A (ja) | 2025-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014876A2 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| CR20220182A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) | |
| EA202191177A1 (ru) | 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8 | |
| EA202091709A1 (ru) | Ингибиторы днк-пк | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| MX2024001017A (es) | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. | |
| CL2019000986A1 (es) | 1,3 di sustituto ciclobutano o derivados de azetidina como inhibidores de prostaglandina d sintasa hematopoyética(h-pgds). | |
| ECSP17085494A (es) | Piridinas sustituidas y método de uso | |
| CO2017004530A2 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| CO2021002977A2 (es) | Dimetilaminoazetidinaminas como inhibidores de jak | |
| MX2022010309A (es) | Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. | |
| EA202092750A1 (ru) | Соединения ингибиторы vmat2, композиции и способы, относящиеся к ним | |
| ECSP18026386A (es) | Sales de un inhibidor de pim quinasa | |
| CL2022000758A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| MX2024007220A (es) | Psicoplastogenos de pirrolidina fusionada y sus usos. | |
| CL2022000757A1 (es) | Tienopirimidonas como inhibidores de trpa1 | |
| MX2024010344A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| MX2018004524A (es) | Derivados de eter ciclico de pirazolo[1,5-a]pirimidin-3-carboxiami da. | |
| MX2021011575A (es) | Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios. | |
| BR112017008026A2 (pt) | processos de produção de composições com melhor perfil de segurança que possui atividade de lipase e composições apropriadas para uso farmacêutico | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| MX2024007221A (es) | Psicoplastogenos sustituidos con fenoxi y benciloxi y sus usos. | |
| MX2024007017A (es) | Procesos para la preparacion de la forma cristalina a de selpercatinib. un inhibidor ret. |